Allakos surges on reverse merger deal with Concentra Biosciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2025
0mins
Source: SeekingAlpha
Merger Announcement: Allakos has agreed to be acquired by Concentra Biosciences for $0.33 per share, with the deal expected to close in May, leading to a 46% increase in Allakos' stock price.
Board Approval: The Board of Directors of Allakos unanimously supports the acquisition, and key stakeholders representing nearly 8% of shares have committed to tendering their shares during the upcoming offer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
